Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.
You may also be interested in...
The Hype And Hope Of Cancer Stem Cell Therapeutics
A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.
AACR’s “Most Likely To Succeed” Anticancer Technologies
The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:
AACR’s “Most Likely To Succeed” Anticancer Technologies
The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include: